AstraZeneca has unveiled new Phase 3 data on the efficacy of its Bruton tyrosine kinase (BTK) inhibitor Calquence (acalabrutinib) in the treatment of previously-treated patients with chronic lymphocytic leukaemia (CLL), demonstrating that the therapy “significantly increased the time patients live without disease progression” in interim analysis.
In the study, 310 participants were randomised into two groups, with one group receiving Calquence 100mg twice daily, and the second group receiving rituximab plus either Roche’s Mabthera (idelalisib) or Gilead’s Zydelig (bendamustine).
